These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 15616148)
1. Topotecan in the first-line treatment of small cell lung cancer. Stewart DJ Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148 [TBL] [Abstract][Full Text] [Related]
2. Emerging role of weekly topotecan in recurrent small cell lung cancer. Eckardt JR Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147 [TBL] [Abstract][Full Text] [Related]
3. Topotecan in the treatment of recurrent small cell lung cancer: an update. Ardizzoni A Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145 [TBL] [Abstract][Full Text] [Related]
4. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353 [TBL] [Abstract][Full Text] [Related]
5. Update on the role of topotecan in the treatment of non-small cell lung cancer. Stewart DJ Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149 [TBL] [Abstract][Full Text] [Related]
6. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K; Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462 [TBL] [Abstract][Full Text] [Related]
7. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010 [TBL] [Abstract][Full Text] [Related]
8. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920 [TBL] [Abstract][Full Text] [Related]
9. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Hainsworth JD; Greco FA Semin Oncol; 1999 Feb; 26(1 Suppl 2):60-6. PubMed ID: 10190785 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Hainsworth JD; Burris HA; Greco FA Semin Oncol; 2001 Apr; 28(2 Suppl 4):43-7. PubMed ID: 11479897 [TBL] [Abstract][Full Text] [Related]
11. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347 [TBL] [Abstract][Full Text] [Related]
12. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Gralla RJ Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146 [TBL] [Abstract][Full Text] [Related]
13. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related]
14. Recent advances with topotecan in the treatment of lung cancer. O'Brien M; Eckardt J; Ramlau R Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613 [TBL] [Abstract][Full Text] [Related]
15. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
17. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814 [TBL] [Abstract][Full Text] [Related]